Xencor (XNCR) Return on Capital Employed (2014 - 2026)
Xencor (XNCR) reported Return on Capital Employed of 28.96% for Q1 2026, down 908.0% year-over-year from 3.58% in Q1 2025, and down 26.64% quarter-over-quarter from 22.87% in Q4 2025.
Xencor (XNCR) Return on Capital Employed (2014 - 2026) Analysis & Trends
Xencor (XNCR) has 13 years of Return on Capital Employed data on file, last reported at 28.96% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 28.96%, down 908.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 28.96% (down 908.0% YoY), and the FY2025 annual result was 21.7%, down 122.0% from the prior year.
- Return on Capital Employed declined to 28.96% in Q1 2026 per XNCR's latest filing, from 22.87% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 10.91% in Q1 2022 and troughed at 28.96% in Q1 2026.
- A 5-year average of 14.89% and a median of 19.62% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2023: Return on Capital Employed jumped 2491 bps in 2022, then sank 3325 bps in 2023.
- A 5-year view of Return on Capital Employed shows it stood at 10.62% in 2022, then tumbled by 56 bps to 16.59% in 2023, then fell by 21 bps to 20.08% in 2024, then declined by 14 bps to 22.87% in 2025, then retreated by 27 bps to 28.96% in 2026.
- Business Quant data shows XNCR's Return on Capital Employed at 28.96% in Q1 2026, 22.87% in Q4 2025, and 17.4% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - | -28.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.96% |
| Dec 31, 2025 | -22.87% |
| Sep 30, 2025 | -17.40% |
| Jun 30, 2025 | -18.18% |
| Mar 31, 2025 | -19.88% |
| Dec 31, 2024 | -20.08% |
| Sep 30, 2024 | -23.22% |
| Jun 30, 2024 | -19.62% |
| Mar 31, 2024 | -14.69% |
| Dec 31, 2023 | -16.59% |
| Sep 30, 2023 | -20.35% |
| Jun 30, 2023 | -22.47% |
| Mar 31, 2023 | -22.33% |
| Dec 31, 2022 | -10.62% |
| Sep 30, 2022 | 6.87% |
| Jun 30, 2022 | 6.26% |
| Mar 31, 2022 | 10.91% |
| Dec 31, 2021 | 6.28% |
| Sep 30, 2021 | -9.44% |
| Jun 30, 2021 | -5.71% |